Abbott Launches TriClip Device in India for Treatment of Leaky Tricuspid Valve

Abbott, a major player in global healthcare, has unveiled the TriClip™ transcatheter edge-to-edge repair (TEER) system in India, marking the arrival of an innovative treatment for tricuspid regurgitation—commonly known as a leaky tricuspid valve.

The device functions by accessing the heart through a vein in the leg, where it clips together portions of the valve's tissue flaps to restore proper blood flow. This approach eliminates the need for invasive open-heart surgery. Drawing on proven technology from the MitraClip system used for mitral valve repair, TriClip incorporates a specialized delivery mechanism tailored for the heart's right side. Most patients require just one day of hospitalization before returning home.

The tricuspid valve regulates blood movement from the heart's right atrium into the right ventricle. When this valve malfunctions, blood flows backward, forcing the heart to work harder. This condition produces symptoms including fatigue and breathlessness, and if neglected, can progress to atrial fibrillation and heart failure. For patients whose symptoms persist despite medical management and who face significant surgical risks, TriClip offers a way to enhance quality of life and reduce hospital admissions related to heart failure.

Tricuspid regurgitation represents an expanding health concern across India, particularly affecting elderly patients and those with rheumatic heart disease, atrial fibrillation, pulmonary hypertension, or other valve complications. Though increasingly recognized in clinical settings, the condition remains significantly underdiagnosed, with research demonstrating that meaningful cases frequently occur during routine cardiac evaluations and tend to worsen without intervention.

"Patients with tricuspid regurgitation have struggled with inadequate therapeutic choices for years, compromising their wellbeing," stated Sudheer Mirajkar, Country Manager for Abbott's Structural Heart business in India. "Introducing TriClip marks a pivotal step forward, delivering a minimally invasive solution that addresses symptoms and transforms patient outcomes. By expanding our structural heart portfolio in India with TriClip, Abbott continues delivering transformative treatments for those managing cardiovascular disease."

The tricuspid valve's intricate anatomy has historically received less clinical focus than other cardiac valves, partly because symptoms emerge gradually and treatment alternatives were scarce. Nevertheless, this valve proves essential for cardiac function. Its soft, tissue-based flaps move with each heartbeat, and its wide, asymmetrical structure sits on the heart's right side where individual anatomical variation is substantial. The valve's performance depends closely on the dimensions and motion of the adjoining heart chamber, meaning even minor alterations can compromise its effectiveness. These characteristics render it exceptionally difficult to address therapeutically, underscoring why contemporary innovation in this space matters significantly.

Clinical evidence supports TriClip's effectiveness and safety. The U.S. Food and Drug Administration's review process examined data from the TRILUMINATE Pivotal trial, a groundbreaking randomized, controlled study comparing TriClip outcomes to medical therapy alone in patients with severe tricuspid regurgitation who faced elevated surgical risk. Results revealed that roughly 90% of TriClip recipients showed substantial improvement in their tricuspid regurgitation classification, progressing from severe or higher grades to moderate or lower within 30 days—a benefit maintained through the one-year mark. The trial documented a robust safety record, with 98% of patients experiencing no major adverse events by day 30, alongside meaningful quality-of-life gains. Extended two-year follow-up data indicated the TriClip system lowered heart failure-related hospitalizations by 28%, with sustained enhancements in valve function and patient wellbeing.